{"id":"6-tioguanine-standard-maintenance-therapy","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Allopurinol","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Azathioprine","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Cyclophosphamide","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Fludarabine","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Methotrexate","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Pentostatin","action":"Avoid","effect":"Increased risk of myelosuppression"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased immune response"}],"commonSideEffects":[],"contraindications":["Hypersensitivity","prior resistance to 6-thioguanine or mercaptopurine"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"Usual Pediatric Dose for: * Acute Myeloid Leukemia * Acute Nonlymphocytic Leukemia","Renal impairment":"Data not available","Hepatic impairment":"Caution recommended"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=6-tioguanine-standard-maintenance-therapy","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:38.199878+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:45.663645+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:52:38.224169+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=6-tioguanine-standard-maintenance-therapy","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:52:46.367088+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:47.486612+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL727/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:47.397591+00:00"}},"allNames":"6-tioguanine+standard maintenance therapy","offLabel":[],"timeline":[],"_dailymed":null,"brandName":"6-tioguanine+Standard Maintenance Therapy","ecosystem":[],"isGeneric":true,"mechanism":{"target":"DNA replication","novelty":"me-too","modality":"small molecule","drugClass":"purine analog","explanation":"","oneSentence":"","technicalDetail":"6-thioguanine acts as a purine analog, which is incorporated into DNA, leading to DNA replication errors and cell death. This results in the inhibition of cancer cell growth and proliferation. The drug's mechanism of action is specific to rapidly dividing cells, making it effective in treating leukemias."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:38.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"$0","genericStatus":"Generic — off-patent","currentRevenue":"52.11 million","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=6-tioguanine-standard-maintenance-therapy","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=6-tioguanine-standard-maintenance-therapy","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:49.388413+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Methotrexate","company":"Jylamvo, Methotrexate LPF","advantage":"Used for treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis"},{"name":"Isotretinoin","company":"Accutane","advantage":"Used for Acute Nonlymphocytic Leukemia"},{"name":"Mitoxantrone","company":"Company not specified","advantage":"Used for Acute Nonlymphocytic Leukemia"},{"name":"Cyclophosphamide","company":"Company not specified","advantage":"Used for Acute Nonlymphocytic Leukemia"},{"name":"Daunorubicin","company":"Company not specified","advantage":"Used for Acute Nonlymphocytic Leukemia"},{"name":"Ozempic","company":"Company not specified","advantage":"Used for type 2 diabetes treatment, weight management, cardiovascular"},{"name":"Novantrone","company":"Company not specified","advantage":"Used for acute nonlymphocytic leukemia, multiple sclerosis, non-hodgkin's lymphoma"},{"name":"Cytoxan","company":"Company not specified","advantage":"Used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer"},{"name":"Cerubidine","company":"Company not specified","advantage":"Used for acute lymphocytic leukemia, acute myeloid leukemia, acute nonlymphocytic leukemia"}],"genericName":"6-tioguanine-standard-maintenance-therapy","indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"},{"name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":"Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma","enrollment":9350},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT00103285","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-04-11","conditions":"Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":5377},{"nctId":"NCT02141100","phase":"PHASE1, PHASE2","title":"Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma","status":"WITHDRAWN","sponsor":"Kjeld Schmiegelow","startDate":"2014-07","conditions":"Non-Hodgkin Lymphoma","enrollment":0},{"nctId":"NCT00005945","phase":"PHASE3","title":"Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":"Leukemia","enrollment":3054},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":"Leukemia","enrollment":2039}],"_emaApprovals":[{"date":"","name":"6-tioguanine+Standard Maintenance Therapy","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL727","moleculeType":"Small molecule","molecularWeight":"167.20"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL727"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:49.388413+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}